[go: up one dir, main page]

MX2020010201A - Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado. - Google Patents

Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.

Info

Publication number
MX2020010201A
MX2020010201A MX2020010201A MX2020010201A MX2020010201A MX 2020010201 A MX2020010201 A MX 2020010201A MX 2020010201 A MX2020010201 A MX 2020010201A MX 2020010201 A MX2020010201 A MX 2020010201A MX 2020010201 A MX2020010201 A MX 2020010201A
Authority
MX
Mexico
Prior art keywords
conjugate
cytotoxic drug
prodrug form
cytotoxic
self
Prior art date
Application number
MX2020010201A
Other languages
English (en)
Inventor
Oleksandr Koniev
Sergii Kolodych
Jean - Yves Bonnefoy
Original Assignee
Syndivia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndivia filed Critical Syndivia
Publication of MX2020010201A publication Critical patent/MX2020010201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un conjugado específico de fármacos citotóxicos y a formas de profármacos de dichos conjugados, para usar en el tratamiento del cáncer y enfermedades inflamatorias. El conjugado está representado por la fórmula (I) en donde A representa un radical que se deriva de un fármaco citotóxico, G es un resto autodestructivo, y m es 0 o 1, y las sales farmacéuticamente aceptables de los mismos.
MX2020010201A 2018-04-03 2019-04-02 Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado. MX2020010201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305390 2018-04-03
PCT/EP2019/058226 WO2019192979A1 (en) 2018-04-03 2019-04-02 Conjugate of cytotoxic drug and prodrug form of said conjugate

Publications (1)

Publication Number Publication Date
MX2020010201A true MX2020010201A (es) 2020-12-10

Family

ID=61965888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010201A MX2020010201A (es) 2018-04-03 2019-04-02 Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.

Country Status (21)

Country Link
US (1) US20210023113A1 (es)
EP (1) EP3773735B1 (es)
JP (1) JP7397058B2 (es)
KR (1) KR20210018208A (es)
CN (1) CN112004556A (es)
AU (1) AU2019248589A1 (es)
CA (1) CA3095146A1 (es)
DK (1) DK3773735T3 (es)
EA (1) EA202092361A1 (es)
ES (1) ES2989309T3 (es)
FI (1) FI3773735T3 (es)
HR (1) HRP20241363T1 (es)
HU (1) HUE068574T2 (es)
IL (1) IL277693B2 (es)
LT (1) LT3773735T (es)
MX (1) MX2020010201A (es)
PL (1) PL3773735T3 (es)
PT (1) PT3773735T (es)
RS (1) RS66033B1 (es)
SM (1) SMT202400404T1 (es)
WO (1) WO2019192979A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114437151B (zh) * 2020-11-03 2023-12-01 华东师范大学 白蛋白结合型喜树碱衍生物前药及其制备方法与应用
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN114085256B (zh) * 2021-11-23 2024-03-19 江南大学 一种β-半乳糖苷酶响应的糖类衍生物及其应用
CN114957356B (zh) * 2022-06-17 2024-10-01 江南大学 一种β-葡萄糖醛酸酶响应的糖类衍生物及其制备方法与应用
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
EP3066120B1 (en) 2013-11-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Synthetic single domain antibody
FR3017298B1 (fr) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Also Published As

Publication number Publication date
PL3773735T3 (pl) 2025-01-20
IL277693A (en) 2020-11-30
IL277693B1 (en) 2023-10-01
IL277693B2 (en) 2024-02-01
JP7397058B2 (ja) 2023-12-12
SMT202400404T1 (it) 2024-11-15
CA3095146A1 (en) 2019-10-10
EP3773735A1 (en) 2021-02-17
PT3773735T (pt) 2024-10-10
HUE068574T2 (hu) 2025-01-28
EA202092361A1 (ru) 2021-02-02
JP2021520409A (ja) 2021-08-19
LT3773735T (lt) 2024-10-25
FI3773735T3 (fi) 2024-10-14
US20210023113A1 (en) 2021-01-28
AU2019248589A1 (en) 2020-10-22
ES2989309T3 (es) 2024-11-26
DK3773735T3 (da) 2024-10-21
KR20210018208A (ko) 2021-02-17
CN112004556A (zh) 2020-11-27
WO2019192979A1 (en) 2019-10-10
RS66033B1 (sr) 2024-11-29
EP3773735B1 (en) 2024-07-10
HRP20241363T1 (hr) 2024-12-20

Similar Documents

Publication Publication Date Title
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
SA520420033B1 (ar) مركبات صيدلية
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
NZ777871A (en) Small molecule modulators of il-17
JOP20200154A1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
PH12021552482A1 (en) Compounds targeting prmt5
CL2024000067A1 (es) Compuestos antivirales
PH12021552217A1 (en) Macrocyclic azolopyridine derivatives as eed and prc2 modulators
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
SA521421855B1 (ar) مترافقات عقار-جسم مضاد
PH12022550597A1 (en) Azole-fused pyridazin-3(2h)-one derivatives
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
ZA202006071B (en) Antiproliferation compounds and uses thereof
PH12021552513A1 (en) Pyrrole compounds
PH12020551772A1 (en) Oxo-substituted compound
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
PH12021552953A1 (en) Tricyclic compounds